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Introduction: The development of effective treatments for osteoarthritis (OA) has been hampered by a poor
understanding of OA at the cellular and molecular levels. Emerging as a disease of the ‘whole joint’, the importance
of the biochemical contribution of various tissues, including synovium, bone and articular cartilage, has become
increasingly significant. Bathing the entire joint structure, the proteomic analysis of synovial fluid (SF) from
osteoarthritic shoulders offers a valuable ‘snapshot’ of the biologic environment throughout disease progression.
The purpose of this study was to identify differentially expressed proteins in early and late shoulder osteoarthritic SF
in comparison to healthy SF.
Methods: A quantitative 18O labeling proteomic approach was employed to identify the dysregulated SF proteins
in early (n = 5) and late (n = 4) OA patients compared to control individuals (n = 5). In addition, ELISA was used to
quantify six pro-inflammatory and two anti-inflammatory cytokines.
Results: Key results include a greater relative abundance of proteins related to the complement system and the
extracellular matrix in SF from both early and late OA. Pathway analyses suggests dysregulation of the acute phase
response, liver x receptor/retinoid x receptor (LXR/RXR), complement system and coagulation pathways in both
early and late OA. The network related to lipid metabolism was down-regulated in both early and late OA.
Inflammatory cytokines including interleukin (IL) 6, IL 8 and IL 18 were up-regulated in early and late OA.
Conclusions: The results suggest a dysregulation of wound repair pathways in shoulder OA contributing to the
presence of a ‘chronic wound’ that progresses irreversibly from early to later stages of OA. Protease inhibitors were
downregulated in late OA suggesting uncontrolled proteolytic activity occurring in late OA. These results contribute
to the theory that protease inhibitors represent promising therapeutic agents which could limit proteolytic activity
that ultimately leads to cartilage destruction.Introduction
Arthritis is a disabling and debilitating disease that is esti-
mated to affect 50 million people or 22% of adults in the
United States, with 21 million or 9% of all adults having
some limitation due to the disease [1]. As the population
advances in both size and age, it has been projected that* Correspondence: clevelandshoulder@gmail.com
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reproduction in any medium, provided the or67 million adults, aged 18 years or older, will be affected
by this disease by 2030 [2]. With current annual costs of
$128 billion, these statistics demonstrate the ever-
increasing burden osteoarthritis (OA) will have on the
healthcare industry [1]. Given the alarming numbers and
increasing economic strain, there is an urgent need to
identify key biomarkers that allow for targeted drug
therapeutics.
A great deal of variance exists in regards to the preva-
lence of OA in the body’s joints. It has been found that the
incidence of OA is disproportionately concentrated in
weight-bearing joints such as the hip and knee. Hip and
knee replacement surgeries accounted for 35% of totall Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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last year [3]. In 2004, there were 454,652 total knee re-
placements, 232,857 total hip replacements, 41,934 total
shoulder replacements and 12,055 other joint replacements
in the United States [4]. While the clinical outcome of OA
is clearly similar in weight-bearing and non-weight-bearing
joints, the biologic similarity is less recognized.
Many candidate molecules have been identified as poten-
tial promoters and regulators of OA progression, but none
have proven to be both necessary and sufficient. Various
matrix metalloproteinases (MMPs) have been implemented
as key contributors to the erosion of articular cartilage in-
cluding MMP-3 [5]. Several proinflammatory cytokines
have been implicated as possible therapeutic targets with
existing research indicating that IL-1β, IL-6 and TNF-α are
the major proinflammatory cytokines in OA [6]. Synovial
macrophages and macrophage released cytokines are
known to cause destruction of articular cartilage [7]. The
complement system has also been described by Wang et al.
as being a key contributor to OA progression. Their group
found that the dysregulation of complement in mice (com-
ponent 5 (C5), C6 or the complement regulatory protein
(CD59a) proved to be key factors in the onset and patho-
genesis of OA [8].
Although the clinical manifestations - cartilage degener-
ation, pathological changes in the subchondral bone and
irritation of the synovium - are well-documented, it is evi-
dent that OA remains poorly understood at the cellular
and molecular level. Various etiologic factors including
age, sex, genetics, trauma, overuse, anatomical abnormal-
ities and obesity have been identified and their interplay
culminates in patient reports of pain and dysfunction [9].
Traditionally, OA was thought to be a disease concen-
trated in the articular cartilage but, as described above, the
complexity of OA is now well appreciated and it is cur-
rently viewed as a disease of the whole joint. Bathing all
structures within the joint, synovial fluid (SF) provides a
snapshot of the entire biologic environment throughout
disease progression. With many tissues contributing to
OA pathogenesis, it is crucial that the entire environment
be studied throughout disease progression so that the con-
tribution of each tissue might be appreciated.
Mass spectrometry allows for the rapid detection and
quantification of proteins composing specific tissues
within the body. This technique has been refined and
developed to a point where increases in sensitivity and
resolution have resulted in higher accuracy when identi-
fying peptides in complex tissues. This study aims to
analyze early and late stages of OA progression through
the proteomic analysis of SF and then compare these
biologic environments to that of a normal shoulder con-
trol group. Studying this snapshot of the biologic envir-
onment throughout disease progression should help to
identify key pathogenic contributors.Methods
Patient cohort
Informed consent was obtained from 90 patients, from
whom 59 samples were collected. The patient population
studied consisted of 16 individuals (8 male and 8 female),
with an average age of 58 years (range 37 to 74). Samples
were collected prior to trocar placement or initial incision
in order to minimize blood contamination of the accessed
joint space. All samples for the study were collected from
patients within our tertiary care referral center. All aspects
of sample collection were approved by the University
Hospitals Institutional Review Board in Cleveland, Ohio.
Control individuals: the control group consisted of six
patients (three male/three female) with an average age of
54 years (30 to 60). These patients were without any prior
history of shoulder surgery, blood dyscrasias, cancer,
chondrocalcinosis or corticosteroid injection within the
past eight weeks. Radiographic and/or magnetic resonance
(MR) imaging demonstrated a normal joint space without
any visible degenerative changes. Samples that were free
from visible blood contamination and consisted of a mini-
mum of 300 μl were collected.
Patients with early OA: the early-stage OA group con-
sisted of five patients (two male/three female) with an aver-
age age of 57 years (50 to 66). Patients who displayed early
pathologic changes in synovium and articular cartilage were
identified through radiographic, MR or arthroscopic im-
aging. Patients undergoing arthroscopic labral repair were
preferentially used for this group as this tissue is relatively
avascular and thus, least likely to contribute a confounding
inflammatory response to our proteomic profile. Again
these patients were without clinically significant shoulder
trauma, blood dyscrasias, cancer, chondrocalcinosis or cor-
ticosteroid injection within the past eight weeks. Samples
that were free from visible blood contamination and con-
sisted of a minimum of 300 μl were collected.
Patients with late OA: the late stage OA group consisted
of five patients (two male/three female) with an average
age of 64 years (47 to 74) who displayed advanced degen-
erative changes in all aspects of the glenohumeral joint
such that a total shoulder replacement was necessary. Ex-
clusion criteria based on the above co-morbidities were
also used for this cohort. Samples that were free from vis-
ible blood contamination and consisted of a minimum of
300 μl were collected.Materials
We purchased oxygen-18 (18O)-water (97%) from Isotec
(Miamisburg, OH, USA). HPLC solvents were purchased
from Fisher scientific Honeywell, B&J HPLC Water
Muskegon, MI, USA. The 16O-water used in all experi-
ments was HPLC grade. The multiple affinity removal col-
umn was purchased from Agilent Technologies (Palo Alto,
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from TCI America (Portland, OR, USA). All other reagents
were of the highest quality commercially available.
SF sample preparation
An 18-gauge needle was inserted into the glenohumeral
joint and up to 4 mL of SF was removed. A stock solution
consisting of one tablet of complete protease inhibitor
cocktail tablets was mixed in 2 mL of 1 × PBS (Roche
Applied Science, Indianapolis, IN, USA). This solution
was then added to the collected SF sample in a 1:4 dilution
in a 5-mL cryogenic tube. The sample was vortexed and
then centrifuged at 402 × g for 10 minutes to remove any
blood contamination. The SF was then removed with a pip-
ette and transferred to a separate cryogenic tube and snap-
frozen in liquid nitrogen and placed in an −80°C freezer.
At the time of processing, the samples were thawed on
ice and the protein amount was estimated with a DC pro-
tein assay kit (Bio-Rad, Hercules, CA, USA) using bovine
serum albumin as a standard protein. To this, 1 μg/mL of
bovine hyaluronidase (Sigma-Aldrich, St. Louis, MO,
USA) was added and the sample was placed in a 37°C
water bath for 3 hours.
Immunodepletion
Each sample was then processed to deplete the 14 most
abundant proteins in SF using an Agilent high capacity
multiple affinity removal spin cartridge according to
manufacturer’s instructions. Buffer exchange to 0.1 M
ammonium bicarbonate (ABC) was performed using
centrifugal filter units -3 K (Amicon® Ultra, Millipore,
Carrigtwohill, Co.Cork, Ireland) and centrifuged at
6,000 × g for 20 minutes at 4°C to bring the pH to an al-
kaline level. This procedure was repeated three times for
each sample. SDS-PAGE was performed to ensure that
the depletion column was working properly throughout
the experiment.
Proteomic sample preparation for immunodepleted SF
Immunodepleted samples (n = 5) from control/healthy
groups were pooled and labeled with 18O and individual
samples from experimental groups were labeled with
16O. The procedure used for one set of pooled control/
individual diseased samples is as described earlier [10].
Protein amount was estimated with a DC protein
assay kit (Bio-Rad) using bovine serum albumin as a
standard protein. We reduced 100 μg of low abundant pro-
teins from pooled healthy samples and the individual dis-
eased sample and these were alkylated by using 21 mM
triethyl phosphine (TEP) and 58 mM iodoethanol (IE). The
samples were then dried in a Speed-vac concentrator and
dissolved in 100 μL of 0.1 M ABC containing 1% PFOA.
Trypsin was added in the ratio of 1 μg per 50 μg of protein.
The samples were placed in a 37°C water bath for 18 hours.A 1:1:1 solution of ethanol, ethyl acetate and HPLC-grade
water with 0.1% TFA was added to the peptide digest and
dried in a Speed-vac concentrator to remove PFOA [10].
The digest was then subjected to 18O labeling as follows:
40 μL of 18O buffer (50 mM ammonium acetate, pH 5.5)
and trypsin were added to the dried samples and the
process was repeated for the 16O samples. The samples
were incubated at 37°C for 18 hours. The reaction was
stopped by drying the samples and adding 50 mM ABC
containing isopropyl alcohol (final concentration = 70%).
The enzyme was inactivated by reducing (TEP/aceto-
nitrile) at 45°C for 1 hour and then alkylating (iodoetha-
nol/acetonitrile) in the dark at 45°C for 2 hours as
described previously [10]. The 18O- and 16O-labeled sam-
ples were mixed in a 1:1 ratio and chromatographed on a
C18 column (3.5 μ, 4.6 × 150 mm, WatersXterra® MS col-
umn Waters XTerra colum XTerra®, MS C18 3.5 um 4.6
× 150 mm Waters corporation 34 maple street Milford,
Massachussets) using a linear gradient of acetonitrile from
0% to 90% in 30 mM ammonium formate (pH 10.0) over a
period of 60 minutes at a flow rate of 400 μl/minute in a
Thermo Finnigan HPLC system. The effluent was moni-
tored by the absorbance at 215 nm. The effluent was col-
lected every minute. The peptide fractions were dried in a
Speed-vac, dissolved in 0.1% formic acid, pooled into 10
fractions, and stored until analyzed by liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS). A total of
five biological replicates from early and late sets were ana-
lyzed by mass spectrometry. Out of five biological repli-
cates from late-stage OA samples, one had to be discarded
due to heavy contamination by blood cells.Proteomic sample preparation for SF proteins bound to
high capacity multiple affinity removal spin cartridge
SF proteins bound to the high capacity multiple affinity re-
moval spin cartridge were also analyzed by fractionating
proteins by SDS-PAGE followed by in-gel 18O labeling.
Protein concentrations were measured using the Biorad
DC protein assay kit. Equal concentrations of proteins
from the control and diseased sample sets were separated
on 4 to 20% polyacrylamide gel and visualized by colloidal
Coomassie stain. Eight slices of exact equal size (excluding
serum albumin protein band) from healthy and diseased
sample sets were excised and subjected to trypsin digestion
as described earlier [11]. In short, gel slices were subjected
to reduction/alkylation using triethyl phosphine/iodoetha-
nol and then de-stained. Gel pieces were saturated with
trypsin buffer and digested with trypsin overnight. The
peptides were extracted, subjected to labeling and mixed as
described earlier in this manuscript. Control/healthy pep-
tides were treated with 16O and diseased peptides were
treated with 18O water, and mixed, and this was subjected
to LC-MS/MS.
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The protein digests were analyzed by LC-MS/MS using an
UltiMate 3000 LC system (Dionex, San Francisco, CA,
USA) interfaced to an LTQ-Orbitrap XL mass spectrom-
eter (Thermo-Finnigan, Bremen, Germany). The platform
operated in the nano-LC mode using the standard nano-
ESI API stack fitted with a picotip emitter (uncoated fit-
ting, 10-μm spray orifice, New Objective, Inc., Woburn,
MA, USA). The solvent flow rate through the column was
maintained at 300 nL/minute using a 1:1,000 splitter sys-
tem. The protein digests (5 μL) were injected into a
reverse-phase C18 PepMap trapping column (0.3 × 5 mm,
5-μm particle size, Dionex Inc.), equilibrated with 0.1%
formic acid/2% acetonitrile (v/v) and washed for 5 minutes
with the equilibration solvent at a flow rate of 25 μL/mi-
nute using an isocratic loading pump operated through an
auto-sampler. After the washing step, the trapping column
was switched in line with a reversed-phase C18 Acclaim
PepMap 100 column (0.075 × 150 mm, Dionex Inc.) and
the peptides were chromatographed using a linear gradi-
ent of acetonitrile from 4.8% to 40% in aqueous 0.1%
formic acid over a period of 90 minutes at the above-
mentioned flow rate, such that the eluate was directly
introduced to the mass spectrometer. An 80% acetonitrile
elution step was subsequently performed for 5 minutes
prior to resetting the analytical column to the initial
equilibration conditions for 11 additional minutes at the
end of the chromatographic run. The mass spectrometer
was operated in a data-dependent MS to MS/MS switch-
ing mode, with the five most intense ions in each MS scan
subjected to MS/MS analysis. The full scan was performed
at 60,000 resolution in the Orbitrap detector and the MS/
MS fragmentation scans were performed in the ion trap
detector (IT) CID mode such that the total scan-cycle fre-
quency was approximately 1 s. The threshold intensity for
the MS/MS trigger was always set at 1,000 and the frag-
mentation was carried out using the CID mode and nor-
malized collision energy (NCE) of 35. The data were
collected in the profile mode for the full scan and centroid
mode for the MS/MS scans. The dynamic exclusion func-
tion for previously selected precursor ions was enabled
during the analysis such that the following parameters
were applied: repeat count of two, repeat duration of 45 s,
exclusion duration of 60 s and exclusion size list of 150.
Xcalibur software (version 2.0.7, Thermo-Finnigan Inc.)
was used for instrument control, data acquisition, and data
processing.
Mass spectrometry data analysis
Mass Spectrometry MS raw data files were searched
against the Swiss-Prot (version 57) database using Mascot
database search software (version 2.1.04, Matrix Science,
London, UK) to identify peptides/proteins with the follow-
ing parameters: S-hydroxyethylation of cysteine as a fixedmodification, and oxidation of methionine to methionine
sulfoxide and 18O labeling of peptide at the C-terminus as
variable modifications. The mass tolerance for the precur-
sor ion was set to 10 ppm, and for the product ion it was
set to 0.8 Da. Strict trypsin specificity was applied, allow-
ing for one missed cleavage. Peptides with a minimum
score of 20 were considered as significant. In-house soft-
ware employing a least-squares regression algorithm [12]
was used for the calculation of 16O/18O peptide ratios.
This software plots 16O/18O-peptide intensities of all pep-
tides identified from the same protein, and the slope of
the linear regression fit is used as a 16O/18O peptide ratio
for that protein. Only proteins with an r2 ≥0.85 and a lin-
ear regression F-probability >0.85 are reported as quanti-
fied proteins. Proteins with r2 values or F-probabilities out
of our range were manually investigated for possible
peptide outliers. An obvious outlier was defined as a pep-
tide whose removal changed the protein r2 value by more
than 0.2 or increased the F-probability to >0.85. If an obvi-
ous outlier was detected, it was removed from the peptide
list. Median normalization of the linear regression ratio
was performed at the protein level within the sets to
account for intra-experimental variation [13]. Following
normalization, protein ratios from all runs were visualized
using histograms. Scattered plot matrices of biological
replicates were generated and the Pearson product mo-
ment correlation coefficient between biological replicates
was calculated using Bioconductor [14]. Fold changes in
the linear regression ratio of proteins were calculated
using Excel. P-values were calculated using the limma
package available in Bioconductor employing the empir-
ical Bayes method [15]. The gplots package from Biocon-
ductor was used to generate heat maps of protein sets
[16]. The color coding is derived using the ranking of the
log ratio in the distribution of measures for that sample.
Shades of red represent downregulation, and shades of
green represent upregulation. The intensity of the color is
determined by the distance (in SD) from the mean of the
trimmed distribution.
Western blot analysis
Commercial antibodies used for western blot validation
experiments were as follows: aggrecan (MA3-16888),
tenascin (MA1-26779) and complement factor D (GAU
008-01-02) monoclonal antibodies (ThermoScientific
Pierce Protein Research Products (Rockford, IL, USA).
SF (processed and unprocessed) was used for western
analysis. SDS-PAGE was performed on 4 to 15% acryl-
amide gels with 30 μg protein applied per lane, and pro-
teins were electrophoretically transferred to nitrocellulose
membranes (Millipore, Billerica, MA, USA). Membranes
were blocked with blocking buffer purchased from LI-
COR (Lincoln, NE) and then incubated overnight at 4°C
with primary antibody. The dilutions were performed as
Figure 1 Schematic representation of proteomic analysis of
shoulder joint synovial fluid.
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washed with PBS containing 0.1% Tween 20 and probed
with secondary antibody (Antimouse 680 antibody from
LICOR, diluted to 1:10,000) in blocking buffer containing
0.1% Tween 20 for 1 hour at room temperature. Proteins
were detected using a LICOR Odyssey Scanner.
Cytokine analysis by ELISA
SF was analyzed from five healthy subjects, and five with
early and five with late stages of OA. SF cytokines were
analyzed using commercially available kits. A kit contain-
ing IL-1β, IL-6, TNF-α, IL-8, IL-17, IL-10, IL-4 and IL-13
was procured from BioLegend (San Diego, CA, USA), and
IL-18 was purchased separately from Medical & Biological
laboratories (Nagoya, Japan). Assays were performed ac-
cording to the manufacturer’s instructions. Manufacturer-
reported precision and sensitivity data for these kits are as
follows: IL-10 = <2 pg/mL, IL-13 = 5.8 pg/mL, IL-6 =
1.6 pg/mL, IL-4 = 0.6 pg/mL, TNF-α = 3.5 pg/mL, IL-1β =
0.5 pg/mL, IL-8 = 4.4 pg/mL, IL-17A = 11.5 pg/mL and
IL-18 = 12.5 pg/mL.
Bioinformatic analysis
Differentially expressed proteins were analyzed using
IPA (version 8.8) (Ingenuity® Systems, [17]) to determine
the functions and pathways most strongly associated
with the proteome set. Proteins with fold change values
of 1.5 above and −1.5 below were uploaded into the
application and analysis was performed to generate net-
works and canonical pathway analysis. The Benjamini-
Hochberg multiple testing correction was applied to as-
sess the significance of associations.
Uric acid analysis
Uric acid concentration of SF samples was measured
using the Uric Acid Assay Kit (No-KA1651, Abnova
Corporation, Walnut, CA). The assay was performed ac-
cording to the manufacturer instructions. The uric acid
concentration of the samples was calculated as:
ΔA590nm sample–ΔA590 blankð Þ= ΔA590nm standard–ΔA590 blankð Þ
10 mg=dLð Þ:
Results
Quantitative proteomic analysis of immunodepleted SF
To quantify differentially expressed proteins from
osteoarthritic SF, we employed the proteolytic 18O label-
ing approach. A schematic representation of the SF
proteomic workflow employed is depicted in Figure 1.
SF is similar to serum with a small number of highly
abundant proteins representing almost 95% of total pro-
tein content, thus making detection of low-abundance
proteins difficult [18]. Consequently, we used a HighCapacity Multiple Affinity Removal Spin Cartridge to
remove 14 abundant proteins from SF. Healthy pooled
samples (n = 6) were labeled with 18O and individual
samples from early (n = 5) and late (n = 4) OA were la-
beled with 16O as described in the Methods section.
The labeled peptide samples were first fractionated by
high-pH reverse-phase chromatography, and then each
fraction subjected to LC-MS/MS analysis. Proteins identi-
fied with one or more peptides with ≤1% false discovery
rate (FDR) were used for subsequent statistical and bio-
informatics analyses. The abundance ratios, presented as
early or late OA patient over the healthy control group, and
the molecular identities of these proteins in the five early
OA versus control experiments and four late OA versus
control experiments are summarized in Additional file 1:
Table S1-Early1-5 and 1-Late1-4, respectively.
Additional file 1: Table S1 lists the complete data set in-
cluding peptide sequences quantified, and Additional file 2:
Figure 2 Histogram plots of immunodepleted proteomic samples. Sample sets early osteoarthritis (EOA) 1–5 are biological replicates from
early-stage OA patients and sample sets late OA (LOA) 1–4 are biological replicates from late-stage OA patients. Log2 of protein ratios and nor-
malized protein ratios are plotted on the x axis and estimated densities of log ratios on the y axis. The black curve represents experimental pro-
tein regression ratios; red and blue curves represent normalized ratios for early and late sample sets, respectively.
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cession number, protein name, number of peptides used
in the protein quantification, abundance ratio, and fold
changes (OA/healthy). The protein ratio and normalized
ratios from each of the biological sets were visualized
by histogram plots (Figure 2). We found 106 and 118
proteins in all the biological replicates within the early OA
(Additional file 3: Table S3A) and late OA (Additional
file 3: Table S3B) subgroups. To check the correlation be-
tween biological replicates, scatter plot matrices of these
proteins in each biological set against other replicates
within the subgroup were generated (Figure 3) and the
Pearson product moment correlation was calculated. The
correlation coefficient varied from 0.63 to 0.87 in early OA
sets and 0.42 to 0.76 in late OA sets suggesting a positive
correlation between the biological replicates within sub-
groups. Probability values for early and late OA sets are
given in Additional file 3: Tables S3A and S3B, respectively.
Quantitative proteomic analysis of SF proteins bound to
high capacity multiple affinity removal spin cartridge
In addition to the immunodepleted samples, SF proteins
bound to the high capacity multiple affinity removal spin
cartridge were also analyzed to obtain the whole picture
of proteins dysregulated in the diseased sample sets.Proteins were fractionated by SDS-PAGE and quantified
by in-gel 18O labeling followed by LC-MS/MS. Of the 14
immunodepleted abundant proteins, Alpha-1-antitrypsin,
Alpha-2-macroglobulin, serotransferrin and immu-
noglobulin molecules were differentially regulated
in early OA sets (Additional file 4: Table S4A), and
alpha-1-antitrypsin, apolipoprotein A-I, haptoglobin,
alpha-1-acid glycoprotein 1, transthyretin and im-
munoglobulin molecules were differentially regulated
in late OA sets (Additional file 4: Table S4B).
Data analyses
A total of 106 and 118 proteins were quantified across
early- and late-stage OA samples, respectively (Additional
file 2: Table S2), of which 31 and 38 proteins were differen-
tially expressed with average fold-change values of ≥1.5
and ≤ −1.5 (Additional file 4: Table S4). These results sug-
gest that most of the dysregulated proteins are already in
place early in the development of the disease, characterizing
a diseased proteome that is distinct from a healthy prote-
ome. The heat map of proteomic alterations from the
immunodepleted early and late OA sets show consistency
across biological replicates (Figure 4). Analyses of altered
proteins from immunodepleted samples as well as proteins
bound to the high capacity multiple affinity removal spin
Figure 3 Scatter plot matrix of immunodepleted proteomic samples. Correlation scattered plot matrix analysis of early (EOA) (A) and late
osteoarthritis (LOA) (B) sample sets. Pearson product moment correlation coefficient of each set with respect to other individual sets is
represented. Clustering can be seen in several plots and positive correlation is seen between sample sets.
Wanner et al. Arthritis Research & Therapy 2013, 15:R180 Page 7 of 13
http://arthritis-research.com/content/15/6/R180cartridge (Additional file 5: Table S5) by The Database
for Annotation, Visualization and Integrated Discovery
(DAVID) showed complement proteins, proteoglycans and
immunoglobulins to be dysregulated in both early and late
OA sets, whereas serine protease inhibitors (serpins) were
dysregulated only in late OA sets.Figure 4 Heat maps of early- and late-stage osteoarthritis (OA) sets. D
(A) and late OA (LOA) (B) sets are represented in the form of a heat map.
were above 1.5/below −1.5. Gene symbols are listed when known. Rows re
EOA and LOA. Upregulated and downregulated proteins are indicated in s
determined by the distance (in SD) from the mean of the trimmed distribuPathway analysis by Ingenuity systems suggests the dys-
regulation of wound repair pathways in SF in both the
early and late OA subgroups (Figure 5A). The normal re-
sponse to tissue injury occurs in three distinct overlapping
stages. The first stage of wound repair is inflammation
followed by activation of the complement system and theifferentially expressed low abundant proteins from early OA (EOA)
The fold changes of proteins considered from biological replicates
present the proteins and columns represent the biological replicates in
hades of green and red, respectively, where the intensity of the color is
tion.
Figure 5 Functional analysis of early and late sets. (A) Comparison of pathway analysis between early and late sets. A probability value of
0.05 was applied for the analysis. (B) Top network Cellular Development, Hematological System Development and Function, Hematopoiesis
associated with the early sample set (C) Top network Organismal Injury and Abnormalities, Respiratory Disease, Cell-To-Cell signaling and Inter-
action associated with the late sample set. Red color indicates higher level of expression in disease and green color indicates lower level of
expression in disease. The names of the genes are in nodes. The shape of the nodes is related to gene function/family membership. The
lines between the nodes represent the connectivity between genes. Solid lines indicate direct protein-protein interactions. Dotted lines rep-
resent indirect interactions.
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formation followed by remodeling of this new tissue.
The top canonical pathway identified in both early and
late OA sets was the acute phase response pathway,
which is a rapid inflammatory response pathway seen
in cases of tissue injury. Dysregulation of another in-
flammatory pathway, liver x receptor/retinoid x recep-
tor (LXR/RXR) was seen in both early and late OA sets.
Increased expression of complement molecules were
also observed in both early and late OA sets. Activationof the coagulation pathway suggests an ongoing effort
by the body to seal the wound formed in the shoulder
joint. A network related to the hematological system
was dysregulated in early OA, whereas organismal in-
jury was dysregulated in late OA sets (Figure 5B and
C). Networks related to lipid metabolism, molecular
transport, small molecule biochemistry were downregu-
lated in both early and late OA sets (data not shown).
Pathways affecting new tissue formation/remodeling
were not seen in either early or late OA sets.
Table 1 Cytokine concentrations in synovial fluid from
healthy subjects (n = 5, pooled), and patients with early-






























The numeric values depicted for EOA and LOA samples are mean ± SD
(concentration range). aCytokine concentrations depicted for healthy synovial
fluid samples (n = 5) are values obtained from pooled samples. EOA, early
osteoarthritis; LOA, late osteoarthritis.
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Proinflammatory cytokines play a major role in the patho-
genesis of OA. SF from healthy, and early- and late-stage
OA patients was quantified for six pro-inflammatory and
two anti-inflammatory cytokines (Table 1). Mean cytokine
concentrations of pro-inflammatory cytokines IL6, IL8
and IL18 were higher in diseased conditions when com-
pared to healthy subjects (Figure 6). A modest increase
was observed with anti-inflammatory cytokine IL10.
Western blot validation
For verification of our mass spectrometry results, western
blot analysis of three differentially expressed proteins (tenas-
cin, complement factor D and aggrecan) was carried out
(Figure 7). These proteins were selected on the basis of in-
teresting biological function and high fold-change, as well as
availability of commercial antibodies. Tenascin and aggrecan
were increased in early OA and slightly decreased in late
OA. Complement factor D was decreased in both early andlate OA. Thus, western blotting corroborated the results of
mass spectrometry analysis (Additional file 1: Table S1).
Uric acid analyses
Research by Denoble and co-workers recently found uric
acid levels to be highly correlated with synovial fluid IL-
18 and IL-1β, which paralleled an increase in OA joint
pathology [20]. Although other crystals (that is, calcium
pyrophosphate dihydrate (CPPD) and basic calcium
phosphate hydroxy-apatite (BCP)) have been shown to
be associated with joint pathology, the high positive cor-
relation between uric acid levels and OA joint pathology
found in the referenced literature provided an interesting
and easily attainable accession to our study. Thus, we
determined the concentration of uric acid from shoulder
SF from healthy subjects and patients with early and late
stages of OA. Uric acid analysis of SF failed to show sig-
nificant differences between the healthy subjects, pa-
tients with early OA and patients with late OA. The
results obtained for the samples are as follows: 3.08 for
pooled healthy, 3.05 ± 0.99 for early (n = 5) and 3.10 ±
1.08 for late (n = 4) samples.
Discussion
As most studies have focused on knee (weight-bearing
joint) OA, less is known about the pathogenesis of shoul-
der OA (non-weight bearing joint). Thus, we have
employed quantitative proteomic techniques to elucidate
the pathological pathways of OA in shoulder SF through
disease progression. Our results clearly show pathological
pathways present in osteoarthritic samples, which exhibit
a similar pattern to those present in other osteoarthritic
joints, particularly the knee [21]. Comparison of early and
late OA samples identified 31 and 38 differentially regu-
lated proteins respectively, many of which have already
been identified previously in SF of other osteoarthritic
joints [21,22]. This differential profile provides potential
insights into the pathophysiology of shoulder OA. Of the
differentially regulated proteins, proteins belonging to the
complement system, extracellular matrix proteins, serpins
and immunoglobulin classes were prominently identified.
Serpins are a superfamily of proteins that inhibit serine
proteases. They are known to control processes such as
inflammation and coagulation [23,24]. We have identified
several serpins in late-OA samples that are downregulated
(Figure 4B). Consistent with our result, SERPINA1, the
most abundant inhibitor in SF, has been reported to be
downregulated in both the early and late OA sets [24].
These results suggest that serine protease activities are un-
regulated in SF, leading to cartilage destruction in OA
[25]. Hence, serpin molecules may be potential therapeutic
agents that could help control matrix degradation in OA.
The complement system is known to play a significant
role in host defense and inflammation. Overexpression
Figure 6 Cytokine analyses. Mean concentration values (n = 5) of cytokines are plotted with error bars representing SD. Values for healthy
samples are from the pooled set (n = 6). EOA, early osteoarthritis; LOA, late osteoarthritis.
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seen in both early OA and late OA (Figure 4). Our re-
sults show that complement factor D, which plays a key
role in the alternate complement pathway, was down-
regulated in early OA (Figure 4A). This supports the
importance of the classical complement system in
shoulder OA which corroborates with a recent study
that established a central role of the classical comple-
ment system in OA in a mouse model [8].
Early- and late-stage OA is characterized by a loss of
proteoglycans. Degeneration of articular cartilage is ob-
served in early OA, and extensive fissuring, fibrillation,
clustering of chondrocytes and loss of cartilage is observed
in late OA. Historically, a severe loss of extracellularFigure 7 Western blot analysis. Tenascin, complement factor D
and aggrecan were analyzed from pooled healthy (H-P), pooled
early (E-P) and pooled late (L-P) sample sets: 50 μg of protein extract
was loaded into each lane.matrix proteins has also been observed in late OA [26].
Our results demonstrated a downregulation of extracellu-
lar matrix proteins in both early and late sets (Figure 4).
Thus, our results are consistent with earlier findings in SF
from horses with induced OA [27].
Increased amounts of aggrecan and cartilage oligoma-
trix protein (COMP) fragments have been observed in
early stages but not in advanced stages [28]. However, a
recent study found increased levels of aggrecan and
COMP fragments in the SF and serum of knee OA pa-
tients [29]. Reduced mRNA levels of aggrecan from
osteoarthritic cartilage have been noted earlier [30].
Western blot analysis for aggrecan in early and late OA
samples passed through the immunodepletion column
gave a single band (Figure 7) while unprocessed samples
gave two bands (data not shown). Additional experi-
ments will need to be carried out to investigate the na-
ture of the fragments arising from aggrecan. Increases in
the concentration of tenascin (Figure 7) was also ob-
served in early OA sets but was slightly downregulated
in late OA sets, which may be the result of the repara-
tive response of the injured tissue, as tenascin is known
to be overexpressed in osteoarthritic cartilage according
to a previous report [30].
In our study, an increased concentration of apolipo-
protein B, the most abundant protein, was observed in
early OA sets whereas a less significant change was ob-
served in late OA sets (Figure 4). Increased levels of
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studies [31]. However, one interesting result to point out
is that lower levels of paroxonase activity have been re-
ported in OA [32] which corroborates with our results
from early OA sets (Figure 4).
Among the proteins that were bound to the high cap-
acity multiple affinity removal spin cartridge, increased
alpha 2 macroglobulin, was observed in both early OA
and late OA (Additional file 4: Table S4) as seen in a
previous study [33]. The protein is known to complex
with MMPs [34] which may eventually lead to deterior-
ation of articular cartilage. Our group also observed
that immunoglobulin molecules were upregulated in
both early and late sets, suggesting underlying joint
inflammation.
The present study examined the presence of interleu-
kins in SF of shoulder OA patients (Figure 6). Proinflam-
matory cytokines, IL-6, IL-8 and IL18, were found to be
increased in early and late OA SF. Significant increases
in IL6, IL8 and IL18 have been reported in SF of the
knee [20,35]. IL-6 is a proinflammatory cytokine that is
markedly upregulated during tissue inflammation [36].
In addition, it has been shown to induce proteoglycan
degradation and inhibit chondrocyte proliferation [37].
IL-8 is known to promote altered chondrocyte differenti-
ation and calcification in OA [38]. IL18 may induce
prostaglandin E2 in SF, thus promoting cartilage damage
[39]. Among anti-inflammatory cytokines only IL10
showed a modest increase in SF. Increases in IL-10 in SF
of OA patients have also been reported [37], which is
known to decrease the production of IL-1β and TNF
alpha, and inhibit prostaglandin E2 (PGE2) [39,40].
The results observed with regard to uric acid concen-
tration in healthy, and early- and late-stage OA samples
in this study, failed to show significant differences. Our
results are in contrast to those found in an earlier paper
[20], suggesting that the glenohumeral joint, a non-
weight bearing joint, may not accumulate uric acid in a
predictive fashion as has been reported in the knee
(weight bearing joint). Additional investigation is neces-
sary to understand the biological principles that underlie
these differences.
Extracellular matrix proteins like aggrecan and COMP
are promising biomarkers in knee OA for early diagnosis
[41]. Cartilage degradation proteins, aggrecan, and
COMP are downregulated considerably in early OA sets
as well as late OA sets. These two proteins may serve as
promising diagnostic biomarkers in early diagnosis as
well as monitoring therapeutic modalities.
Conclusion
The presented proteomic study is the first to analyze SF
from patients with shoulder OA. Aggrecan and COMP
proteins have the potential to be developed as diagnosticbiomarkers. A promising lead obtained from our study
in understanding shoulder OA, is the expression of pro-
tease inhibitors in the late-stage OA sets. Downregula-
tion of serpins may eventually lead to uncontrolled
activity of proteases resulting in matrix destruction. De-
velopment of specific protease inhibitors as potential
therapeutic agents may lessen the destruction of cartil-
age in shoulder OA. Ultimately, this may help to develop
new treatment modalities leading to effective disease
management.Additional files
Additional file 1: Table S1. Information contained in this table is
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